Thursday, June 24th, 2004 - Alimta® Receives CHMP Positive Opinion for Two Cancer Indications: Recommended for Approval to Treat Malignant Pleural Mesothelioma and Lung Cancer
- Home
- Asbestos Diseases:
- Asbestos:
- Hope & Help:
- Information & Resources:
- Contact:
News Categories
- 9/11 Asbestos Risks (4)
- Asbestos & Mesothelioma Studies (90)
- Asbestos Abatement (74)
- Asbestos Bankruptcies (1)
- Asbestos in Products (14)
- Asbestos in Schools (24)
- Asbestos Legislation (53)
- Drug Companies (83)
- ImClone Systems Incorporated (1)
- Alfacell (27)
- Bristol-Myers Squibb (1)
- CuraGen (1)
- Eli Lilly (19)
- Fujirebio Diagnostics, Inc. (9)
- Genentech (1)
- Innovive Pharmaceuticals (3)
- NeoPharm, Inc. (1)
- Raptor Pharmaceuticals Corporation (1)
- Rosetta Genomics (6)
- Solbec Pharmaceuticals Ltd (1)
- TopoTarget (1)
- Zengen, Inc. (1)
- Full Archive (382)
- Libby, MT (15)
- Novel Treatments & Drugs (99)
- Avastin (3)
- Carboplatin (Paraplatin®) (8)
- Cisplatin (Platinol ®) (11)
- Coramsine (1)
- Gemcitabine (1)
- histone deacetylase inhibitors (1)
- melanocortin receptors (MCR) subtypes MC1R and MC3R (1)
- MESOMARK (8)
- Mesothelioma Blood Test (12)
- Onconase (ranpirnase) (23)
- Pemetrexed (Alimta) (28)
- Raltitrexed (Tomudex®) (1)
- Organizations (199)
- Polio Vaccine – Simian Virus 40 (SV40) (3)
- Trust Funds (10)
Meso News Archives:
-
You are currently browsing the Mesothelioma News weblog archives for June, 2004.
